RxDoctor Payments DataLook up a doctor →

Carmela Luzi

Medical · Newtown, CTNPI 1538540257

Payments from drug & device makers

$13,238in general payments, 2019–2025

Across 699 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Novartis$1K
  • UCB, Inc.$908
  • Sun Pharmaceutical Industries Inc.$889
  • plus $6K from 23 others

What the payments were for

  • Food & beverage$12,74996%
  • Education$4884%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,238 in reported general payments places this provider in the 95th percentile of 592 medical providers in Connecticut.

See all medical providers in Connecticut

Medicare billing

Part B allowed, 2024
$228,674
Medicare patients
496
Services billed
3,882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyriziRisankizumab-Rzaa13$268,171
Cosentyx Unoready PenSecukinumab18$205,248
Bimzelx AutoinjectorBimekizumab-Bkzx13$189,061
Dupixent PenDupilumab13$48,647
Clobetasol Propionate61$2,194
Metronidazole40$2,077
Fluorouracil30$1,687
Ketoconazole99$1,515
Ciclopirox23$1,372
Triamcinolone Acetonide115$1,168
Fluocinonide28$1,101
ValacyclovirValacyclovir Hcl18$1,035
Betamethasone Dipropionate30$978
Nystatin78$789
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc34$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSkyrizi$2,381$268,17113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 592 medical providers in Connecticut.

Other medical in Newtown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →